{
  "as_of_date": null,
  "programs": [],
  "_llm_parse_error": "Expecting value: line 1 column 1 (char 0)",
  "_llm_raw_output": "```json\n{\n  \"as_of_date\": \"October 14, 2025\",\n  \"programs\": [\n    {\n      \"asset\": \"AKEEGA (niraparib/abiraterone)\",\n      \"indication\": \"M1 Metastatic Castration-Sensitive Prostate Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": \"AMPLITUDE\",\n      \"partner\": \"TESARO, an oncology-focused business within GSK\",\n      \"notes\": null\n    },\n    {\n      \"asset\": \"DARZALEX (daratumumab)\",\n      \"indication\": \"Smoldering Multiple Myeloma\",\n      \"phase\": null,\n      \"trial_or_program\": \"AQUILA\",\n      \"partner\": \"Genmab A/S\",\n      \"notes\": null\n    },\n    {\n      \"asset\": \"DARZALEX (daratumumab)\",\n      \"indication\": \"Frontline multiple myeloma transplant ineligible\",\n      \"phase\": null,\n      \"trial_or_program\": \"CEPHEUS\",\n      \"partner\": \"Genmab A/S\",\n      \"notes\": null\n    },\n    {\n      \"asset\": \"IMBRUVICA (ibrutinib)\",\n      \"indication\": \"Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)\",\n      \"phase\": null,\n      \"trial_or_program\": \"GLOW\",\n      \"partner\": \"Pharmacyclics, LLC, an AbbVie company\",\n      \"notes\": null\n    },\n    {\n      \"asset\": \"IMBRUVICA (ibrutinib)\",\n      \"indication\": \"Frontline Mantle Cell Lymphoma\",\n      \"phase\": null,\n      \"trial_or_program\": \"Triangle\",\n      \"partner\": \"Pharmacyclics, LLC, an AbbVie company\",\n      \"notes\": null\n    },\n    {\n      \"asset\": \"INLEXZO (gemcitabine intravesical system)\",\n      \"indication\": \"Non Muscle Invasive Bladder Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": \"SunRISe-1\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"RYBREVANT (amivantamab)\",\n      \"indication\": \"Frontline Non Small Cell Lung Cancer in combination with chemotherapy\",\n      \"phase\": null,\n      \"trial_or_program\": \"PAPILLON\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"RYBREVANT (amivantamab)\",\n      \"indication\": \"Subcutaneous\",\n      \"phase\": null,\n      \"trial_or_program\": \"PALOMA-3\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"Bleximenib\",\n      \"indication\": \"Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine\",\n      \"phase\": null,\n      \"trial_or_program\": \"cAMeLot-2\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"CARVYKTI (Ciltacabtagene autoleucel)\",\n      \"indication\": \"Frontline Multiple Myeloma TNI\",\n      \"phase\": null,\n      \"trial_or_program\": \"CARTITUDE-5\",\n      \"partner\": \"Legend Biotech\",\n      \"notes\": null\n    },\n    {\n      \"asset\": \"CARVYKTI (Ciltacabtagene autoleucel)\",\n      \"indication\": \"Frontline Multiple Myeloma Transplant Eligible vs ASCT\",\n      \"phase\": null,\n      \"trial_or_program\": \"CARTITUDE-6\",\n      \"partner\": \"Legend Biotech\",\n      \"notes\": null\n    },\n    {\n      \"asset\": \"ERLEADA (apalutamide)\",\n      \"indication\": \"Localized Prostate Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": \"ATLAS\",\n      \"partner\": \"Regents of California and Memorial Sload Kettering\",\n      \"notes\": null\n    },\n    {\n      \"asset\": \"ERLEADA (apalutamide)\",\n      \"indication\": \"High Risk Prostate Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": \"PROTEUS\",\n      \"partner\": \"Regents of California and Memorial Sload Kettering\",\n      \"notes\": null\n    },\n    {\n      \"asset\": \"INLEXZO (gemcitabine intravesical system)\",\n      \"indication\": \"Non Muscle Invasive Bladder Cancer BCG-naïve High Risk\",\n      \"phase\": null,\n      \"trial_or_program\": \"SunRISe-3\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"INLEXZO (gemcitabine intravesical system)\",\n      \"indication\": \"High Risk Non Muscle Invasive Bladder Cancer BGC Experienced\",\n      \"phase\": null,\n      \"trial_or_program\": \"SunRISe-5\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"JNJ-1900 (NBTXR3)\",\n      \"indication\": \"Head and Neck Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": null,\n      \"partner\": \"Nanobiotix\",\n      \"notes\": null\n    },\n    {\n      \"asset\": \"pasritamig\",\n      \"indication\": \"Prostate Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": null,\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"RYBREVANT (amivantamab)\",\n      \"indication\": \"Colorectal Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": \"ORIGAMI-2\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"RYBREVANT (amivantamab)\",\n      \"indication\": \"Colorectal Cancer 2L\",\n      \"phase\": null,\n      \"trial_or_program\": \"ORIGAMI-3\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"TALVEY + TECVAYLI\",\n      \"indication\": \"Relapsed Refractory Multiple Myeloma CD38 exposed\",\n      \"phase\": null,\n      \"trial_or_program\": \"MonumenTAL-6\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"TALVEY (talquetamab)\",\n      \"indication\": \"Relapsed Refractory Multiple Myeloma A-CD38 Naïve\",\n      \"phase\": null,\n      \"trial_or_program\": \"MonumenTAL-3\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"TALVEY (talquetamab)\",\n      \"indication\": \"Relapsed Refractory Multiple Myeloma CD38 exposed\",\n      \"phase\": null,\n      \"trial_or_program\": \"MonumenTAL-6\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"TALVEY (talquetamab)\",\n      \"indication\": \"TIE NDMM in combination with DR\",\n      \"phase\": null,\n      \"trial_or_program\": \"MajesTEC-7\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"TAR-210 (RIS/erdafitinib)\",\n      \"indication\": \"Intravesical Delivery System for Localized Bladder Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": \"MoonRISe-1\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"TECVAYLI (teclistamab)\",\n      \"indication\": \"Multiple Myeloma 1-3PLs\",\n      \"phase\": null,\n      \"trial_or_program\": \"MajesTEC-3\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"TECVAYLI (teclistamab)\",\n      \"indication\": \"TE NDMM maintenance\",\n      \"phase\": null,\n      \"trial_or_program\": \"MajesTEC-4\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"TECVAYLI (teclistamab)\",\n      \"indication\": \"TIE NDMM in combination with DR\",\n      \"phase\": null,\n      \"trial_or_program\": \"MajesTEC-7\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"TECVAYLI (teclistamab)\",\n      \"indication\": \"Relapsed Refractory Multiple Myeloma CD38 exposed\",\n      \"phase\": null,\n      \"trial_or_program\": \"MajesTEC-9\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"Bleximenib\",\n      \"indication\": \"Relapsed Refractory Acute Myeloid Leukemia\",\n      \"phase\": null,\n      \"trial_or_program\": \"ALE1001\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"JNJ-0683 (ARX788)\",\n      \"indication\": \"Breast Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": null,\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"JNJ-1900 (NBTXR3)\",\n      \"indication\": \"Lung Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": null,\n      \"partner\": \"Nanobiotix\",\n      \"notes\": null\n    },\n    {\n      \"asset\": \"TALVEY + TECVAYLI\",\n      \"indication\": \"Relapsed Refractory Multiple Myeloma\",\n      \"phase\": null,\n      \"trial_or_program\": \"RedirecTT-1\",\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"JNJ-0387\",\n      \"indication\": \"Solid Tumors\",\n      \"phase\": null,\n      \"trial_or_program\": null,\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"JNJ-0631 (ARX305)\",\n      \"indication\": \"Renal Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": null,\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"JNJ-1493\",\n      \"indication\": \"Hematological Malignancies\",\n      \"phase\": null,\n      \"trial_or_program\": null,\n      \"partner\": null,\n      \"notes\": null\n    },\n    {\n      \"asset\": \"JNJ-2638\",\n      \"indication\": \"Gastrointestinal Cancer\",\n      \"phase\": null,\n      \"trial_or_program\": null,\n      \"partn",
  "_meta": {
    "run_date_utc": "2026-01-07",
    "source_url": "https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf",
    "input_text_sha256": "c8346bd17a91794d9b776b0953bb625a6580b4ee8d53710ed2d456500a7a481d"
  }
}